News
Recent Highlights
-
Achieved third quarter 2021 revenue of
$574 thousand , representing 12 Controlled Launch Program participants opting to acquire their CellFX Systems and transition to commercial use -
Onboarded 68 CellFX System Controlled Launch Program participants to date and anticipate the remaining to be onboarded in Q4 to complete program enrollment across the
U.S. ,Europe andCanada - Completed enrollment of 150 patients in an FDA IDE approved pivotal comparison study to assess the treatment of cutaneous non-genital warts using the CellFX System, the corresponding 510(k) submission is on track to be completed in the first half of 2022
- Completed enrollment of 30 patients as part of a feasibility study to assess the treatment of basal cell carcinoma using the CellFX System, on track for tissue analysis to be completed in Q1 2022
-
Strengthened the executive leadership team with the appointment of
Mitchell E. Levinson as Chief Strategy Officer, to spearhead the Company’s multi-specialty expansion efforts to leverage NPS technology, the CellFX platform and CellFX CloudConnect in applications outside of dermatology -
Appointed healthcare industry executive
Laureen DeBuono to its Board of Directors
“We made important progress across the business in the third quarter resulting in our first quarter of revenue as the initial Controlled Launch Program participants elected to purchase their CellFX Systems and Cycle Units for commercial use,” said
Third Quarter 2021 Results
Revenue for the three months ended
Total GAAP gross loss* for the three months ended
Total GAAP operating expenses representing research and development, sales and marketing and general and administrative expenses for the three months ended
GAAP net loss for the three months ended
Cash, cash equivalents and investments totaled
* Gross loss is calculated as total revenues less cost of revenues.
Reconciliations of GAAP to non-GAAP operating expenses and net loss have been provided in the tables following the financial statements in this press release. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”
Webcast and Conference Call Information
Pulse Biosciences’ management will host a conference call today,
About
To stay informed about the CellFX System, please visit CellFX.com and sign-up for updates.
Non-GAAP Financial Measures
In this press release, in order to supplement the Company’s condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for the statement of operations. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results in order to supplement investors’ and other readers’ understanding and assessment of the Company’s financial performance. Company management uses these measurements as aids in monitoring the Company’s ongoing financial performance from quarter to quarter, and year to year, on a regular basis and for financial and operational decision-making. Non-GAAP adjustments include stock-based compensation, depreciation and amortization. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to management and investors. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools. Investors are encouraged to review these reconciliations, and not to rely on any single financial measure to evaluate the Company’s business.
Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies, which could reduce the usefulness of the Company’s non-GAAP financial measures as tools for comparison. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Non-GAAP financial measures in this earnings release exclude the following:
Non-cash expenses for stock-based compensation. The Company has excluded the effect of stock-based compensation expenses in calculating the Company’s non-GAAP operating expenses and net loss measures. Although stock-based compensation is a key incentive offered to employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expense related to grants of performance and time-based options. Depending upon the size, timing and terms of the grants, as well as the probability of achievement of performance-based awards, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons from period to period.
Depreciation and amortization. The Company has excluded depreciation and amortization expense in calculating its non-GAAP operating expenses and net loss measures. Depreciation and amortization are non-cash charges to current operations.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to Pulse Biosciences’ expectations regarding the benefits of the Company’s Controlled Launch program and commercialization of the CellFX System to drive growth, including the timing for onboarding KOLs, broader commercial launch and future regulatory clearances, statements relating to the effectiveness of the Company’s NPS technology and the CellFX System to improve patient outcomes, statements relating to the Company’s current and planned future clinical studies, the timing for completion of such studies, and the ability of the Company to execute such studies, as well as the anticipated results of any such studies, statements relating to the Company’s pipeline of product candidates, market opportunities and commercial launch plans, including the market for aesthetic dermatologic procedures, and statements relating to the impact of COVID-19 and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the
|
|
||||||||
|
Condensed Consolidated Balance Sheets |
||||||||
|
(In thousands, except per share amounts) |
||||||||
|
(Unaudited) |
||||||||
|
|
|
|
||||||
|
2021 |
|
2020 |
||||||
|
ASSETS |
||||||||
|
Current assets: |
||||||||
|
Cash and cash equivalents |
$ |
41,991 |
|
$ |
12,463 |
|
||
|
Investments |
— |
|
8,012 |
|
||||
|
Accounts Receivable |
72 |
|
— |
|
||||
|
Inventory |
4,281 |
|
— |
|
||||
|
Prepaid expenses and other current assets |
2,866 |
|
1,864 |
|
||||
|
Total current assets |
|
49,210 |
|
|
22,339 |
|
||
|
Property and equipment, net |
2,446 |
|
2,478 |
|
||||
|
Intangible assets, net |
3,382 |
|
3,882 |
|
||||
|
|
2,791 |
|
2,791 |
|
||||
|
Right-of-use assets |
8,954 |
|
9,438 |
|
||||
|
Other assets |
365 |
|
365 |
|
||||
|
Total assets |
$ |
67,148 |
|
$ |
41,293 |
|
||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
|
Current liabilities: |
||||||||
|
Accounts payable |
$ |
2,706 |
|
$ |
1,717 |
|
||
|
Accrued expenses |
4,971 |
|
5,326 |
|
||||
|
Deferred revenue |
7 |
|
— |
|
||||
|
Lease liability, current |
749 |
|
542 |
|
||||
|
Note payable, current |
1,086 |
|
— |
|
||||
|
Total current liabilities |
|
9,519 |
|
|
7,585 |
|
||
|
Lease liability, less current |
10,242 |
|
10,814 |
|
||||
|
Total liabilities |
|
19,761 |
|
|
18,399 |
|
||
|
Stockholders’ equity: |
||||||||
|
Preferred stock, |
— |
|
— |
|
||||
|
Common stock, |
29 |
|
25 |
|
||||
|
Additional paid-in capital |
268,142 |
|
195,410 |
|
||||
|
Accumulated other comprehensive income (loss) |
— |
|
(1 |
) |
||||
|
Accumulated deficit |
(220,784 |
) |
(172,540 |
) |
||||
|
Total stockholders’ equity |
|
47,387 |
|
|
22,894 |
|
||
|
Total liabilities and stockholders’ equity |
$ |
67,148 |
|
$ |
41,293 |
|
||
|
|
||||||||||||||||
|
Condensed Consolidated Statements of Operations and Comprehensive Loss |
||||||||||||||||
|
(In thousands, except per share amounts) |
||||||||||||||||
|
(Unaudited) |
||||||||||||||||
|
Three-Month Periods Ended |
|
Nine-Month Periods Ended |
||||||||||||||
|
|
|
|
||||||||||||||
|
2021 |
|
2020* |
|
2021 |
|
2020* |
||||||||||
|
Revenues: |
||||||||||||||||
|
Product revenues |
$ |
574 |
|
$ |
— |
|
$ |
574 |
|
$ |
— |
|
||||
|
Total revenues |
574 |
|
|
— |
|
|
574 |
|
|
— |
|
|||||
|
Cost and expenses: |
||||||||||||||||
|
Cost of revenues |
727 |
|
— |
|
727 |
|
— |
|
||||||||
|
Research and development |
6,460 |
|
6,968 |
|
22,982 |
|
19,019 |
|
||||||||
|
Sales and marketing |
3,404 |
|
1,746 |
|
10,697 |
|
4,926 |
|
||||||||
|
General and administrative |
4,256 |
|
4,191 |
|
13,772 |
|
12,264 |
|
||||||||
|
Total cost and expenses |
|
14,847 |
|
|
12,905 |
|
|
48,178 |
|
|
36,209 |
|
||||
|
Loss from operations |
(14,273 |
) |
(12,905 |
) |
(47,604 |
) |
(36,209 |
) |
||||||||
|
Other income (expense): |
||||||||||||||||
|
Interest income (expense), net |
|
(9 |
) |
|
9 |
|
|
(640 |
) |
|
108 |
|
||||
|
Total other income (expense) |
(9 |
) |
9 |
|
(640 |
) |
108 |
|
||||||||
|
Net loss |
|
(14,282 |
) |
|
(12,896 |
) |
|
(48,244 |
) |
|
(36,101 |
) |
||||
|
Other comprehensive gain (loss): |
||||||||||||||||
|
Unrealized gain (loss) on available-for-sale securities |
— |
|
1 |
|
1 |
|
(3 |
) |
||||||||
|
Comprehensive loss |
$ |
(14,282 |
) |
$ |
(12,895 |
) |
$ |
(48,243 |
) |
$ |
(36,104 |
) |
||||
|
Net loss per share: |
||||||||||||||||
|
Basic and diluted net loss per share |
$ |
(0.48 |
) |
$ |
(0.51 |
) |
$ |
(1.76 |
) |
$ |
(1.60 |
) |
||||
|
Weighted average shares used to compute net loss per common share — basic and diluted |
|
29,612 |
|
|
25,223 |
|
|
27,400 |
|
|
22,540 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Three-Month Periods Ended |
|
Nine-Month Periods Ended |
||||||||||||||
|
|
|
|
||||||||||||||
|
Stock Based Compensation Expense: |
2021 |
|
|
2020* |
|
2021 |
|
|
2020* |
|||||||
|
Cost of revenues |
$ |
37 |
|
$ |
— |
|
$ |
37 |
|
$ |
— |
|
||||
|
Research and development |
418 |
|
1,183 |
|
4,586 |
|
2,957 |
|
||||||||
|
Sales and marketing |
65 |
|
312 |
|
2,326 |
|
903 |
|
||||||||
|
General and administrative |
1,057 |
|
1,154 |
|
4,041 |
|
3,826 |
|
||||||||
|
Total stock-based compensation expense |
$ |
1,577 |
|
$ |
2,649 |
|
$ |
10,990 |
|
$ |
7,686 |
|
||||
|
*Certain 2020 amounts have been reclassified to conform to the current period presentation. Sales and marketing expenses have been reclassified out of general and administrative and presented as a separate line item. Amortization of intangible assets are reclassified to general and administrative expenses. |
||||||||||||||||
|
|
||||||||||||||||||||
|
Consolidated Revenue Financial Highlights |
||||||||||||||||||||
|
(In thousands) |
||||||||||||||||||||
|
(Unaudited) |
||||||||||||||||||||
|
Three-Month Periods Ended |
|
Nine-Month Periods Ended |
||||||||||||||||||
|
|
|
|
||||||||||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
||||||||||
|
Revenue by category: |
||||||||||||||||||||
|
Systems |
$ |
490 |
|
85% |
|
$ |
— |
|
- |
|
$ |
490 |
|
85% |
|
$ |
— |
|
- |
|
|
Cycle units |
84 |
|
15% |
|
|
— |
|
- |
|
|
84 |
|
15% |
|
|
— |
|
- |
||
|
Total revenue |
$ |
574 |
|
100% |
|
$ |
— |
|
- |
|
$ |
574 |
|
100% |
|
$ |
— |
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Revenue by geography: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
$ |
405 |
|
71% |
|
$ |
— |
|
- |
|
$ |
405 |
|
71% |
|
$ |
— |
|
- |
|
|
Rest of World |
169 |
|
29% |
|
|
— |
|
- |
|
|
169 |
|
29% |
|
|
— |
|
- |
||
|
Total revenue |
$ |
574 |
|
100% |
|
$ |
— |
|
- |
|
$ |
574 |
|
100% |
|
$ |
— |
|
- |
|
|
Reconciliation of GAAP to Non-GAAP Financial Measures |
||||||||||||||||
|
The following table presents the reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures: |
||||||||||||||||
|
(In thousands) |
||||||||||||||||
|
(Unaudited) |
||||||||||||||||
|
|
||||||||||||||||
|
Three-Month Periods Ended |
|
Nine-Month Periods Ended |
|
|||||||||||||
|
|
|
|
|
|
|
|||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
|||||
|
Reconciliation of GAAP to non-GAAP Cost of revenues: |
|
|||||||||||||||
|
GAAP Cost of revenues |
$ |
727 |
|
$ |
— |
|
$ |
727 |
|
$ |
— |
|
|
|||
|
Add: Stock-based compensation expense |
(37 |
) |
— |
|
(37 |
) |
— |
|
|
|||||||
|
Add: Depreciation and amortization |
(3 |
) |
— |
|
(3 |
) |
— |
|
|
|||||||
|
Non-GAAP Cost of revenues |
$ |
687 |
|
$ |
— |
|
$ |
687 |
|
$ |
— |
|
|
|||
|
|
||||||||||||||||
|
Reconciliation of GAAP to non- |
|
|||||||||||||||
|
|
$ |
6,460 |
|
$ |
6,968 |
|
$ |
22,982 |
|
$ |
19,019 |
|
|
|||
|
Less: Stock-based compensation expense |
(418 |
) |
(1,183 |
) |
(4,586 |
) |
(2,957 |
) |
|
|||||||
|
Less: Depreciation and amortization |
(43 |
) |
(41 |
) |
(123 |
) |
(123 |
) |
|
|||||||
|
|
$ |
5,999 |
|
$ |
5,744 |
|
$ |
18,273 |
|
$ |
15,939 |
|
|
|||
|
|
||||||||||||||||
|
Reconciliation of GAAP to non-GAAP Sales and marketing: |
|
|||||||||||||||
|
GAAP Sales and marketing |
$ |
3,404 |
|
$ |
1,746 |
|
$ |
10,697 |
|
$ |
4,926 |
|
|
|||
|
Less: Stock-based compensation expense |
(65 |
) |
(312 |
) |
(2,326 |
) |
(903 |
) |
|
|||||||
|
Non-GAAP Sales and marketing |
$ |
3,339 |
|
$ |
1,434 |
|
$ |
8,371 |
|
$ |
4,023 |
|
|
|||
|
|
||||||||||||||||
|
Reconciliation of GAAP to non-GAAP General and administrative: |
|
|||||||||||||||
|
GAAP General and administrative |
$ |
4,256 |
|
$ |
4,191 |
|
$ |
13,772 |
|
$ |
12,264 |
|
|
|||
|
Less: Stock-based compensation expense |
(1,057 |
) |
(1,154 |
) |
(4,041 |
) |
(3,826 |
) |
|
|||||||
|
Less: Depreciation and amortization |
(241 |
) |
(223 |
) |
(722 |
) |
(686 |
) |
|
|||||||
|
Non-GAAP General and administrative |
$ |
2,958 |
|
$ |
2,814 |
|
$ |
9,009 |
|
$ |
7,752 |
|
|
|||
|
|
||||||||||||||||
|
Reconciliation of GAAP to non-GAAP Cost and expenses: |
|
|||||||||||||||
|
GAAP Cost and expenses |
$ |
14,847 |
|
$ |
12,905 |
|
$ |
48,178 |
|
$ |
36,209 |
|
|
|||
|
Less: Stock-based compensation expense |
(1,577 |
) |
(2,649 |
) |
(10,990 |
) |
(7,686 |
) |
|
|||||||
|
Less: Depreciation and amortization |
(287 |
) |
(264 |
) |
(848 |
) |
(809 |
) |
|
|||||||
|
Non-GAAP Cost and expenses |
$ |
12,983 |
|
$ |
9,992 |
|
$ |
36,340 |
|
$ |
27,714 |
|
|
|||
|
|
||||||||||||||||
|
Reconciliation of GAAP to non-GAAP Net loss: |
|
|||||||||||||||
|
GAAP Net loss |
$ |
(14,282 |
) |
$ |
(12,896 |
) |
$ |
(48,244 |
) |
$ |
(36,101 |
) |
|
|||
|
Add: Stock-based compensation expense |
1,577 |
|
2,649 |
|
10,990 |
|
7,686 |
|
|
|||||||
|
Add: Depreciation and amortization |
287 |
|
264 |
|
848 |
|
809 |
|
|
|||||||
|
Non-GAAP Net loss |
$ |
(12,418 |
) |
$ |
(9,983 |
) |
$ |
(36,406 |
) |
$ |
(27,606 |
) |
|
|||
View source version on businesswire.com: https://www.businesswire.com/news/home/20211115006190/en/
Investors:
510.241.1077
IR@pulsebiosciences.com
or
415.937.5406
philip@gilmartinir.com
Media:
Nadine D. Tosk
504.453.8344
nadinepr@gmail.com or
press@pulsebiosciences.com
Source: